Table 3.

Evaluation of studies according to the face validity criteria of Gill and Feinstein

Authors	[ref]	Year	1. Definition of QOL/HRQOL?	2. Domains stated?	3. Reasons for choosing instrument?	4. Aggregate results into single score?	5. Could patients provide a global rating of QOL?	6. Overall QOL and HRQOL distinguished?	7. Patients invited to supplement items?	8. If adherence to item 7, Incorporated into final rating?	9. Could patients rate personally important items?	10. If adherence to item 9, incorporated into final rating	Summary score
Acaster et al.	[38]	2020	0	+	0	+	0	0	0	NA	0	NA	25
Anagnostou et al.	[67]	2014	0	0	0	+	0	0	0	NA	0	NA	12.5
Avery et al.	[8]	2003	0	0	0	+	0	0	+	0	0	NA	22.22
Blackman et al.	[85]	2020	0	+	0	+	0	0	0	NA	0	NA	25
Blümchen et al.	[68]	2019	0	0	0	+	0	0	0	NA	0	NA	12.5
Borres et al.	[39]	2017	0	0	+	0	0	0	0	NA	0	NA	12.5
Burrell et al.	[86]	2021	0	0	0	+	0	0	0	NA	0	NA	12.5
Chow et al.	[40]	2015	0	+	0	+	0	0	0	NA	0	NA	25
Covaciu et al.	[41]	2013	+	+	+	0	0	0	0	NA	0	NA	37.5
Cummings et al.	[42]	2010	0	+	0	+	0	0	0	NA	0	NA	25
d’Art et al.	[69]	2022	0	0	0	+	0	0	0	NA	0	NA	12.5
Danchin et al.	[76]	2016	0	+	0	+	0	0	0	NA	0	NA	25
Dantzer et al.	[70]	2022	0	+	0	+	0	0	0	NA	0	NA	25
Dilley et al.	[43]	2019	0	0	0	+	0	0	0	NA	0	NA	12.5
DunnGalvin et al.	[44]	2009	+	+	0	+	0	0	0	NA	0	NA	37.5
DunnGalvin et al.	[71]	2021	0	+	0	+	0	0	0	NA	0	NA	25
Epstein Rigbi et al.	[45]	2016	0	+	0	+	0	0	0	NA	0	NA	25
Epstein Rigbi et al.	[79]	2017	0	+	0	+	0	0	0	NA	0	NA	25

Authors	[ref]	Year	1. Definition	2. Domains	3. Instrument reasoning	4. Result aggregation	5. Global QOL rating	6. QOL/HRQOL distinction	7. Item supplementation	8. If; included in final rating	9. Personally important items	10. If; included in final rating	Sum score
Epstein Rigbi et al.	[87]	2019	0	+	0	+	0	0	0	NA	0	NA	25
Epstein Rigbi et al.	[78]	2020	0	+	0	+	0	0	0	NA	0	NA	25
Epstein Rigbi et al.	[77]	2021	0	+	0	+	0	0	0	NA	0	NA	25
Fernandez-Rivas et al.	[80]	2022	0	0	0	+	0	0	0	NA	0	NA	12.5
Flokstra-de Blok et al.	[10]	2010a	+	+	+	+	0	0	0	NA	0	NA	50
Flokstra-de Blok et al.	[35]	2010b	0	+	0	+	0	0	0	NA	0	NA	25
Frachette et al.	[46]	2022	0	+	0	+	0	0	0	NA	0	NA	25
Hamada et al.	[88]	2021	0	+	0	+	0	0	0	NA	0	NA	25
Hourihane et al.	[81]	2017	0	0	0	+	0	0	0	NA	0	NA	12.5
Hourihane et al.	[72]	2020	0	0	0	+	0	0	0	NA	0	NA	12.5
Indinnimeo et al.	[47]	2013	+	+	+	+	0	0	0	NA	0	NA	50
Jonsson et al.	[48]	2021	0	+	0	+	0	0	0	NA	0	NA	25
Kelleher et al.	[73]	2013	0	0	0	+	0	0	0	NA	0	NA	12.5
King et al.	[49]	2009	0	+	0	+	0	0	0	NA	0	NA	25
Knibb et al.	[90]	2012	0	0	0	+	0	0	0	NA	0	NA	12.5
Knibb and Hourihane	[82]	2013	0	+	0	+	0	0	0	NA	0	NA	25
Marklund et al.	[50]	2006	0	+	0	+	0	0	0	NA	0	NA	25
Miller et al.	[51]	2020	0	+	0	+	0	0	0	NA	0	NA	25
Morou et al.	[52]	2021	0	0	0	+	0	0	0	NA	0	NA	12.5
Nowak-Wegrzyn et al.	[53]	2021	+	+	0	+	0	+	0	NA	0	NA	50
Protudjer et al.	[54]	2015	0	+	+	+	0	0	0	NA	0	NA	37.5
Protudjer et al.	[55]	2016	+	+	+	+	0	0	0	NA	0	NA	50
Protudjer et al.	[56]	2019	0	0	0	+	0	0	0	NA	0	NA	12.5
Qari et al.	[57]	2020	+	+	0	+	0	0	0	NA	0	NA	37.5
Reier-Nilsen et al.	[74]	2019	0	+	0	0	0	0	0	NA	0	NA	12.5
Roy and Roberts	[36]	2011	+	+	0	+	0	0	0	NA	0	NA	37.5
Roy et al.	[37]	2012	+	+	+	+	0	0	0	NA	0	NA	50
Saleh-Langenberg et al.	[58]	2015	0	+	0	+	0	0	0	NA	0	NA	25
Saleh-Langenberg et al.	[59]	2016	0	0	0	+	0	0	0	NA	0	NA	12.5
Shemesh et al.	[60]	2013	0	+	0	+	0	0	0	NA	0	NA	25
Shemesh et al.	[75]	2017	0	0	0	+	0	0	0	NA	0	NA	12.5
Sicherer et al.	[9]	2001	0	0	0	0	0	0	0	NA	0	NA	0
Stensgaard et al.	[61]	2017	0	0	0	+	0	0	0	NA	0	NA	12.5
Strinnholm et al.	[62]	2017	+	+	0	+	0	0	0	NA	0	NA	37.5
Valentine and Knibb	[91]	2011	+	+	0	+	0	+	0	NA	0	NA	50
van der Valk et al.	[83]	2016	0	+	0	+	0	0	0	NA	0	NA	25
van der Velde et al.	[63]	2011a	0	+	+	+	0	0	0	NA	0	NA	37.5
van der Velde et al.	[64]	2011b	0	+	+	+	0	0	0	NA	0	NA	37.5
van der Velde et al.	[84]	2012	0	+	0	+	0	0	0	NA	0	NA	25
Venter et al.	[65]	2015	0	+	0	+	0	0	0	NA	0	NA	25
Wassenberg et al.	[66]	2012	0	+	0	+	0	0	0	NA	0	NA	25
Yee et al.	[89]	2019	0	+	0	+	0	0	0	NA	0	NA	25
Östblom et al.	[92]	2008	0	+	0	+	0	0	0	NA	0	NA	25
Total			11	43	9	57	0	2	1	0	0	0